Nour Faqeer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nour Faqeer has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Nour Mustafa
Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan
2 shared publications- Tasnim Quran
King Hussein Cancer Center
2 shared publications Ahmad Alyamani
Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan
1 shared publicationAmal AlJammal
Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan
1 shared publicationAyah Habeeb
Department of Pharmacy, King Hussein Cancer Center, Amman, Jordan
1 shared publicationBanan Al Hamad
King Hussein Cancer Center, Amman, Jordan
1 shared publication
Latest Publications
- 11 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Anaphylactic reaction to the second dose of dacarbazine following initial exposure in patient with hodgkin lymphoma
Introduction: Dacarbazine is generally well-tolerated, apart from its hematologic toxicities; however, rare and life-threatening anaphylactic reactions have been reported. We aimed to describe a rare case of anaphylactic reaction to dacarbazine following a previously tolerated first dose. Case Report: We report a case of a 69-year-old male patient with classical Hodgkin lymphoma, who was planned for nivolumab, doxorubicin, vinblastine, and dacarbazine (N + AVD) combination, day 1 and 15 every 28 days. The patient received day 1 of cycle#1, without any complications. On day 15, the patient developed a severe anaphylactic reaction 5 min after the start of dacarbazine infusion. The reaction was manifested by hypoxia, shivering, itching, and laryngeal edema. Management & Outcome: Patient required immediate interruption of dacarbazine infusion and received 10 mg of intravenous chlorphenamine and 200 mg of intravenous hydrocortisone initially with no improvement. Hypoxia and laryngeal edema improved following the administration of 0.3 mg intramuscular epinephrine. The patient was transferred to the intensive care unit for close monitoring due to increased risk of biphasic anaphylactic reaction, in which symptoms can recur after initial resolution. Oxygen saturation improved from 82% to 90–93%, and the patient remained hemodynamically stable without complications. Dacarbazine was discontinued. Patient continued nivolumab, doxorubicin, and vinblastine (N + AV) for five cycles, and achieved complete metabolic response. Discussion: This case highlights that anaphylactic reaction to dacarbazine may occur despite prior tolerance to the first dose. Physicians should suspect reaction during subsequent infusions of dacarbazine, even when initial cycle is tolerated.
- 11 August 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Anaphylactic reaction to the second dose of dacarbazine following initial exposure in patient with hodgkin lymphoma
Introduction: Dacarbazine is generally well-tolerated, apart from its hematologic toxicities; however, rare and life-threatening anaphylactic reactions have been reported. We aimed to describe a rare case of anaphylactic reaction to dacarbazine following a previously tolerated first dose. Case Report: We report a case of a 69-year-old male patient with classical Hodgkin lymphoma, who was planned for nivolumab, doxorubicin, vinblastine, and dacarbazine (N + AVD) combination, day 1 and 15 every 28 days. The patient received day 1 of cycle#1, without any complications. On day 15, the patient developed a severe anaphylactic reaction 5 min after the start of dacarbazine infusion. The reaction was manifested by hypoxia, shivering, itching, and laryngeal edema. Management & Outcome: Patient required immediate interruption of dacarbazine infusion and received 10 mg of intravenous chlorphenamine and 200 mg of intravenous hydrocortisone initially with no improvement. Hypoxia and laryngeal edema improved following the administration of 0.3 mg intramuscular epinephrine. The patient was transferred to the intensive care unit for close monitoring due to increased risk of biphasic anaphylactic reaction, in which symptoms can recur after initial resolution. Oxygen saturation improved from 82% to 90–93%, and the patient remained hemodynamically stable without complications. Dacarbazine was discontinued. Patient continued nivolumab, doxorubicin, and vinblastine (N + AV) for five cycles, and achieved complete metabolic response. Discussion: This case highlights that anaphylactic reaction to dacarbazine may occur despite prior tolerance to the first dose. Physicians should suspect reaction during subsequent infusions of dacarbazine, even when initial cycle is tolerated.
- 8 July 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer
Introduction: Taxane-induced peripheral neuropathy (TIPN) is a debilitating side effect of taxane chemotherapy. However, real-world studies on TIPN requiring treatment are limited. This study evaluated the incidence, characteristics, and outcomes of TIPN requiring treatment in patients with breast cancer. Methods: A retrospective study was conducted at King Hussein Cancer Center and included adult patients with breast cancer treated with taxane-based chemotherapy regimens from January 2023 to August 2025. Patients who developed TIPN requiring pain medications were identified. Baseline characteristics, taxane related data, onset of TIPN requiring treatment, clinical outcomes, and pain management strategies were assessed using descriptive analysis. Results: Among 1353 patients, 201 (15.0%) developed TIPN requiring treatment. The mean age was 54 years (SD ± 10.5). Among these patients, 135 (67.2%) received docetaxel and 66 (32.8%) received paclitaxel. Early-stage breast cancer was reported in 133 (66.0%) patients, while 68 (34.0%) had metastatic disease. TIPN requiring treatment occurred most frequently after the third cycle with docetaxel ( n = 104, 77.0%), and after the fifth cycle with paclitaxel ( n = 30, 45.5%). TIPN requiring treatment resulted in emergency department visits in 16 (8.0%) patients, chemotherapy dose reductions in 63 (31.3%), treatment discontinuation in 23 (11.4%), and cycle delays in 3 (1.5%) patients. Initial pharmacologic management consisted of gabapentin monotherapy (80.0%), duloxetine monotherapy (10.5%), and combination of gabapentin and duloxetine (7.0%). Conclusions: During the study period, TIPN requiring treatment affected one- in- seven patients with breast cancer and resulted in significant treatment modifications, highlighting opportunities for proactive management strategies to improve patient care and safety.
- 8 July 2026
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Incidence and clinical characteristics of taxane-induced peripheral neuropathy requiring treatment in patients with breast cancer
Introduction: Taxane-induced peripheral neuropathy (TIPN) is a debilitating side effect of taxane chemotherapy. However, real-world studies on TIPN requiring treatment are limited. This study evaluated the incidence, characteristics, and outcomes of TIPN requiring treatment in patients with breast cancer. Methods: A retrospective study was conducted at King Hussein Cancer Center and included adult patients with breast cancer treated with taxane-based chemotherapy regimens from January 2023 to August 2025. Patients who developed TIPN requiring pain medications were identified. Baseline characteristics, taxane related data, onset of TIPN requiring treatment, clinical outcomes, and pain management strategies were assessed using descriptive analysis. Results: Among 1353 patients, 201 (15.0%) developed TIPN requiring treatment. The mean age was 54 years (SD ± 10.5). Among these patients, 135 (67.2%) received docetaxel and 66 (32.8%) received paclitaxel. Early-stage breast cancer was reported in 133 (66.0%) patients, while 68 (34.0%) had metastatic disease. TIPN requiring treatment occurred most frequently after the third cycle with docetaxel ( n = 104, 77.0%), and after the fifth cycle with paclitaxel ( n = 30, 45.5%). TIPN requiring treatment resulted in emergency department visits in 16 (8.0%) patients, chemotherapy dose reductions in 63 (31.3%), treatment discontinuation in 23 (11.4%), and cycle delays in 3 (1.5%) patients. Initial pharmacologic management consisted of gabapentin monotherapy (80.0%), duloxetine monotherapy (10.5%), and combination of gabapentin and duloxetine (7.0%). Conclusions: During the study period, TIPN requiring treatment affected one- in- seven patients with breast cancer and resulted in significant treatment modifications, highlighting opportunities for proactive management strategies to improve patient care and safety.
- 16 September 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (1) , 89-95
Impact of Clinical Pharmacists’ Interventions on Medication Use and Direct Cost Savings in an Inpatient Medical Oncology Setting
Introduction: There are limited studies evaluating the impact of clinical pharmacists’ interventions (CPIs) and pharmacist-driven cost savings in the inpatient oncology settings. This study aimed to assess the clinical impact of CPIs and direct cost savings from deprescribing-related interventions in an inpatient oncology service. Methods: A retrospective study was conducted by assessing CPIs extracted from the pharmacy documentation system in the medical oncology service between January 2022 and December 2023. The clinical impact of these CPIs was evaluated through including interventions accepted by physicians and resulted in therapy changes, along with their significance levels. Direct cost savings were calculated for deprescribing interventions, including drug discontinuation and intravenous-to-oral (IV-PO) conversions, based on the cost saved per intervention over a 24-hour period. Results: During the study period, 9995 CPIs were identified, of which, 99.0% (n = 9887) were accepted by physicians and included in the analysis. The most frequent interventions were recommendations for drug additions/dose change (n = 3603, 36.4%), followed by drug discontinuations (n = 2886, 29.0%). Antimicrobials were the most frequently involved drug class (n = 4017, 40.7%). Significant CPIs that improved standard of care accounted for 7274 (73.6%) interventions, while very significant and extremely significant interventions were 2595 (26.3%) and 14 (0.14%), respectively. The overall direct cost savings from deprescribing were $102 710, with drug therapy discontinuations and IV-PO conversions contributing $99 305 and $3405, respectively. Conclusion: CPIs showed significant clinical and financial impact, with a high rate of accepted interventions resulting in therapy changes. Further prospective studies are required to analyze the clinical outcomes and indirect cost savings.
- 16 September 2025
- Published by SAGE Publications in Hospital Pharmacy
- Vol. 61 (1) , 89-95
Impact of Clinical Pharmacists’ Interventions on Medication Use and Direct Cost Savings in an Inpatient Medical Oncology Setting
Introduction: There are limited studies evaluating the impact of clinical pharmacists’ interventions (CPIs) and pharmacist-driven cost savings in the inpatient oncology settings. This study aimed to assess the clinical impact of CPIs and direct cost savings from deprescribing-related interventions in an inpatient oncology service. Methods: A retrospective study was conducted by assessing CPIs extracted from the pharmacy documentation system in the medical oncology service between January 2022 and December 2023. The clinical impact of these CPIs was evaluated through including interventions accepted by physicians and resulted in therapy changes, along with their significance levels. Direct cost savings were calculated for deprescribing interventions, including drug discontinuation and intravenous-to-oral (IV-PO) conversions, based on the cost saved per intervention over a 24-hour period. Results: During the study period, 9995 CPIs were identified, of which, 99.0% (n = 9887) were accepted by physicians and included in the analysis. The most frequent interventions were recommendations for drug additions/dose change (n = 3603, 36.4%), followed by drug discontinuations (n = 2886, 29.0%). Antimicrobials were the most frequently involved drug class (n = 4017, 40.7%). Significant CPIs that improved standard of care accounted for 7274 (73.6%) interventions, while very significant and extremely significant interventions were 2595 (26.3%) and 14 (0.14%), respectively. The overall direct cost savings from deprescribing were $102 710, with drug therapy discontinuations and IV-PO conversions contributing $99 305 and $3405, respectively. Conclusion: CPIs showed significant clinical and financial impact, with a high rate of accepted interventions resulting in therapy changes. Further prospective studies are required to analyze the clinical outcomes and indirect cost savings.
- 24 July 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Characteristics of adverse drug reactions resulting in modifications of antineoplastic therapy plan in patients with breast cancer at a comprehensive cancer center
Introduction: Adherence to standard antineoplastic treatment is associated with improved response in breast cancer patients. However, treatment modifications may be necessary for patients who experience significant adverse drug reactions (ADRs). Limited data exist on the characteristics of ADRs that require such modifications. We aimed to evaluate significant ADRs associated with antineoplastic agents in breast cancer patients. Methods: A retrospective observational study was conducted at King Hussein Cancer Center, included significant ADRs experienced by breast cancer patients between January 2018 and December 2020. We recorded patients’ characteristics, medications involved, the type of ADRs, and the required treatment modifications, including dose reduction, treatment delay, or discontinuation. Descriptive analysis was performed to report the results. Results: During the study period, 597 significant ADRs were reported in 351 patients, with a mean age of 53 years (11.8 SD). Additionally, 65.5% of patients presented with locally advanced disease. Docetaxel (44%) was the most common agent associated with ADRs. Hematologic and gastrointestinal ADRs were the most frequently reported, accounting for 38.0% and 18.0% of ADRs, respectively. Of the reported ADRs, 61.0%, 26.0%, 13.0% resulted in treatment dose reduction, delay and discontinuation of subsequent cycle, respectively. Conclusion: In this study evaluating a relatively large number of significant ADRs, docetaxel was the most common antineoplastic agent requiring treatment modifications. The most frequent modification was dose reduction. Future studies should be directed to identify measures that may reduce the incidence and severity of the ADRs.
- 24 July 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Characteristics of adverse drug reactions resulting in modifications of antineoplastic therapy plan in patients with breast cancer at a comprehensive cancer center
Introduction: Adherence to standard antineoplastic treatment is associated with improved response in breast cancer patients. However, treatment modifications may be necessary for patients who experience significant adverse drug reactions (ADRs). Limited data exist on the characteristics of ADRs that require such modifications. We aimed to evaluate significant ADRs associated with antineoplastic agents in breast cancer patients. Methods: A retrospective observational study was conducted at King Hussein Cancer Center, included significant ADRs experienced by breast cancer patients between January 2018 and December 2020. We recorded patients’ characteristics, medications involved, the type of ADRs, and the required treatment modifications, including dose reduction, treatment delay, or discontinuation. Descriptive analysis was performed to report the results. Results: During the study period, 597 significant ADRs were reported in 351 patients, with a mean age of 53 years (11.8 SD). Additionally, 65.5% of patients presented with locally advanced disease. Docetaxel (44%) was the most common agent associated with ADRs. Hematologic and gastrointestinal ADRs were the most frequently reported, accounting for 38.0% and 18.0% of ADRs, respectively. Of the reported ADRs, 61.0%, 26.0%, 13.0% resulted in treatment dose reduction, delay and discontinuation of subsequent cycle, respectively. Conclusion: In this study evaluating a relatively large number of significant ADRs, docetaxel was the most common antineoplastic agent requiring treatment modifications. The most frequent modification was dose reduction. Future studies should be directed to identify measures that may reduce the incidence and severity of the ADRs.
- 17 July 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Treatment outcomes of hypercalcemia that resulting in hospital admission in cancer patients treated with bisphosphonates in real-world setting
Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.
- 17 July 2025
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
Treatment outcomes of hypercalcemia that resulting in hospital admission in cancer patients treated with bisphosphonates in real-world setting
Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.
- 11 November 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (2) , 276-281
Qualitative analysis of clinical pharmacy interventions in an inpatient leukemia service
Introduction: Leukemia, a complex hematological malignancy, requires a multidisciplinary treatment approach, with clinical pharmacists playing a crucial role. However, their involvement in clinical practice is not well-documented in the literature. This study aimed to examine the characteristics of clinical pharmacy interventions (CPIs) reported by clinical pharmacists. Method: This retrospective study involved extraction of CPIs entered into a pharmacy documentation database “Quantifi ® ” between January 2019 and June 2023. These CPIs included direct clinical pharmacist interventions (DCPIs), detected medication errors (MEs) and adverse drug reactions (ADRs). Results: A total of 6286 CPIs were extracted, of which DCPIs, MEs and ADRs accounted for 5701 (90.7%), 357 (5.7%) and 228 (3.6%) reports, respectively. The most prevalent DCPIs were drug therapy discontinuation (n = 1080, 18.9%). Antimicrobials were the most common medications associated with DCPIs (n = 1991, 34.9%). Physicians accepted 99.4% of DCPIs and 64.1% (n = 3656) of direct interventions were considered significant. Among detected MEs, antimicrobials were the most reported medications (n = 158, 44.3%), with pharmacy internal errors being the most prevalent cause of the events (n = 172, 48.2%). Among the reported ADRs, hematological reactions were the most common (n = 81, 35.5%), and antineoplastic agents were the most frequently associated medications with ADRs (n = 164, 71.9%). Conclusion: This study highlights the crucial role of clinical pharmacists in managing leukemia patients, emphasizing their key interventions and ability to identify MEs and ADRs. Further research is needed to explore the clinical outcomes and financial impact of their involvement.
- 11 November 2024
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 31 (2) , 276-281
Qualitative analysis of clinical pharmacy interventions in an inpatient leukemia service
Introduction: Leukemia, a complex hematological malignancy, requires a multidisciplinary treatment approach, with clinical pharmacists playing a crucial role. However, their involvement in clinical practice is not well-documented in the literature. This study aimed to examine the characteristics of clinical pharmacy interventions (CPIs) reported by clinical pharmacists. Method: This retrospective study involved extraction of CPIs entered into a pharmacy documentation database “Quantifi ® ” between January 2019 and June 2023. These CPIs included direct clinical pharmacist interventions (DCPIs), detected medication errors (MEs) and adverse drug reactions (ADRs). Results: A total of 6286 CPIs were extracted, of which DCPIs, MEs and ADRs accounted for 5701 (90.7%), 357 (5.7%) and 228 (3.6%) reports, respectively. The most prevalent DCPIs were drug therapy discontinuation (n = 1080, 18.9%). Antimicrobials were the most common medications associated with DCPIs (n = 1991, 34.9%). Physicians accepted 99.4% of DCPIs and 64.1% (n = 3656) of direct interventions were considered significant. Among detected MEs, antimicrobials were the most reported medications (n = 158, 44.3%), with pharmacy internal errors being the most prevalent cause of the events (n = 172, 48.2%). Among the reported ADRs, hematological reactions were the most common (n = 81, 35.5%), and antineoplastic agents were the most frequently associated medications with ADRs (n = 164, 71.9%). Conclusion: This study highlights the crucial role of clinical pharmacists in managing leukemia patients, emphasizing their key interventions and ability to identify MEs and ADRs. Further research is needed to explore the clinical outcomes and financial impact of their involvement.
- 23 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 897-901
Impact of clinical pharmacists in an inpatient medical oncology service: A prospective study at a comprehensive cancer center in Jordan
Introduction: Clinical pharmacy is considered an integral discipline in the health care system for optimizing therapy and reducing drug-related problems. The objective of this study was to evaluate the impact of clinical pharmacists in optimizing management in a medical oncology service. Methods: A prospective study was conducted at King Hussein Cancer Center between July 2019 and September 2019 of patients admitted to the medical oncology service. The impact of clinical pharmacists was measured by evaluating their interventions, defined as actions that were expected to result in a change in patient management. Data were collected daily by routine review of patients' profiles and by recording clinical pharmacists’ interventions. The data collected were baseline characteristics of patients, numbers and types of clinical pharmacists’ interventions, their significance, medications involved, and rate of acceptance of clinical pharmacists’ interventions by physicians. The significance of each intervention was assessed by two clinical pharmacists on a Hatoum scale. Physicians’ acceptance was assessed by whether the recommendations were implemented. Results: During the study period, 748 patients were included, of whom 605 required a total of 1683 clinical interventions. The mean age was 56.3 years (±15.5 SD). Of the interventions, 39% resulted in initiation of a drug and 25% in drug discontinuations. The drug group most commonly associated with clinical pharmacists’ interventions was antibiotics (26.5%). Physicians accepted 98% of the clinical pharmacists’ interventions, and 92.4% of the interventions brought care to a more appropriate level and were considered significant. Conclusion: Most patients in the medical oncology service required clinical pharmacists’ interventions, as demonstrated by the high number of significant clinical pharmacists’ interventions. Studies should be conducted to follow up these findings with respect to patient outcomes and cost savings.
- 23 July 2020
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 27 (4) , 897-901
Impact of clinical pharmacists in an inpatient medical oncology service: A prospective study at a comprehensive cancer center in Jordan
Introduction: Clinical pharmacy is considered an integral discipline in the health care system for optimizing therapy and reducing drug-related problems. The objective of this study was to evaluate the impact of clinical pharmacists in optimizing management in a medical oncology service. Methods: A prospective study was conducted at King Hussein Cancer Center between July 2019 and September 2019 of patients admitted to the medical oncology service. The impact of clinical pharmacists was measured by evaluating their interventions, defined as actions that were expected to result in a change in patient management. Data were collected daily by routine review of patients' profiles and by recording clinical pharmacists’ interventions. The data collected were baseline characteristics of patients, numbers and types of clinical pharmacists’ interventions, their significance, medications involved, and rate of acceptance of clinical pharmacists’ interventions by physicians. The significance of each intervention was assessed by two clinical pharmacists on a Hatoum scale. Physicians’ acceptance was assessed by whether the recommendations were implemented. Results: During the study period, 748 patients were included, of whom 605 required a total of 1683 clinical interventions. The mean age was 56.3 years (±15.5 SD). Of the interventions, 39% resulted in initiation of a drug and 25% in drug discontinuations. The drug group most commonly associated with clinical pharmacists’ interventions was antibiotics (26.5%). Physicians accepted 98% of the clinical pharmacists’ interventions, and 92.4% of the interventions brought care to a more appropriate level and were considered significant. Conclusion: Most patients in the medical oncology service required clinical pharmacists’ interventions, as demonstrated by the high number of significant clinical pharmacists’ interventions. Studies should be conducted to follow up these findings with respect to patient outcomes and cost savings.